SUNNYVALE, California, November 21 /PRNewswire/ --
- Acquisition Marks First Robotic Radiosurgery System in Russia, Expanding Patients' Cancer Treatment Options
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the N. N. Blokhin Cancer Research Center in Moscow, Russia has acquired a CyberKnife(R) Robotic Radiosurgery System. Once installed, this will be the first CyberKnife System in Russia, giving patients access to the benefits of robotic radiosurgery.
"We are extremely excited to see the benefits of whole body radiosurgery expand into Russia, the largest and one of the most populated countries in the world," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. "This acquisition paves the way for greater patient access to CyberKnife radiosurgery, thereby providing patients an additional treatment option that can improve their quality of life."
The Blokhin Cancer Research Center comprises four separate Institutes, including a 1,600 bed hospital devoted to cancer patients. It is one of the largest in Europe employing 700 scientists and 2,000 medical personnel. The Blokhin Cancer Research Center is part of the American-Russian Cancer Alliance, which also includes the University of Maryland Greenebaum Cancer Center in Baltimore, Md., the Fox Chase Cancer Center in Philadelphia, Pa., and the Kurchatov Institute. The U.S. National Cancer Institute (NCI) provides the infrastructure for the Alliance.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release regarding procedure growth and market acceptance, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-Q for the quarterly period ended September 29, 2007 and may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Web site: http://www.accuray.com